Herbert Yu, MD, PhD

• Alessandro Santin
• Beth Anne Jones
• Gloria Huang
• Harvey Risch
• Lingeng Lu
• Melinda Irwin
• Pei Hui

Breast Neoplasms; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Uterine Neoplasms; Molecular Epidemiology; Gene-Environment Interaction

• Elucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysisZhong H, Liu S, Zhu J, Xu T, Yu H, Wu L. Elucidating the role of blood metabolites on pancreatic cancer risk using two‐sample Mendelian randomization analysis. International Journal Of Cancer 2023, 154: 852-862. PMID: 37860916, PMCID: PMC10843029, DOI: 10.1002/ijc.34771.
• Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2)Frias-Gomez J, Alemany L, Benavente Y, Clarke M, de Francisco J, De Vivo I, Du M, Goodman M, Lacey J, Liao L, Lipworth L, Lu L, Merritt M, Michels K, O'Connell K, Paytubi S, Pelegrina B, Peremiquel-Trillas P, Petruzella S, Ponce J, Risch H, Setiawan V, Schouten L, Shu X, Trabert B, Van den Brandt P, Wentzensen N, Wilkens L, Yu H, Costas L. Night shift work, sleep duration and endometrial cancer risk: A pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Sleep Medicine Reviews 2023, 72: 101848. PMID: 37716022, PMCID: PMC10840870, DOI: 10.1016/j.smrv.2023.101848.
• Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjectsZhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.
• Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization.King S, Veliginti S, Brouwers M, Ren Z, Zheng W, Setiawan V, Wilkens L, Shu X, Arslan A, Beane Freeman L, Bracci P, Canzian F, Du M, Gallinger S, Giles G, Goodman P, Haiman C, Kogevinas M, Kooperberg C, LeMarchand L, Neale R, Visvanathan K, White E, Albanes D, Andreotti G, Babic A, Berndt S, Brais L, Brennan P, Buring J, Rabe K, Bamlet W, Chanock S, Fuchs C, Gaziano J, Giovannucci E, Hackert T, Hassan M, Katzke V, Kurtz R, Lee I, Malats N, Murphy N, Oberg A, Orlow I, Porta M, Real F, Rothman N, Sesso H, Silverman D, Thompson I, Wactawski-Wende J, Wang X, Wentzensen N, Yu H, Zeleniuch-Jacquotte A, Yu K, Wolpin B, Duell E, Li D, Hung R, Perdomo S, McCullough M, Freedman N, Patel A, Peters U, Riboli E, Sund M, Tjønneland A, Zhong J, Van Den Eeden S, Kraft P, Risch H, Amundadottir L, Klein A, Stolzenberg-Solomon R, Antwi S. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 1265-1269. PMID: 37351909, PMCID: PMC10529823, DOI: 10.1158/1055-9965.epi-23-0453.
• Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in ShanghaiWang S, Xie L, Zhuang J, Qian Y, Zhang G, Quan X, Li L, Yu H, Zhang W, Zhao W, Qian B. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer 2023, 23: 425. PMID: 37165412, PMCID: PMC10173582, DOI: 10.1186/s12885-023-10849-8.
• Abstract 5518: Use of antihypertensive drugs and the risk of cancer, findings of a population-based cohort study in ShanghaiWang S, Xie L, Qian Y, Wang J, Zhang G, Li L, Zhang W, Yu H, Zhao W, Qian B. Abstract 5518: Use of antihypertensive drugs and the risk of cancer, findings of a population-based cohort study in Shanghai. Cancer Research 2023, 83: 5518-5518. DOI: 10.1158/1538-7445.am2023-5518.
• Abstract 3336: A novel clinical and biomarker model accurately predicts hepatocellular carcinoma (HCC) across racial groupsXiang X, Vegesna A, Amdur R, Shetty K, Yu H, Wong L, Fox S, Ryan M, Chambwe N, Satapathy S, Crawford J, Grimaldi G, Kundra V, Mishra L. Abstract 3336: A novel clinical and biomarker model accurately predicts hepatocellular carcinoma (HCC) across racial groups. Cancer Research 2023, 83: 3336-3336. DOI: 10.1158/1538-7445.am2023-3336.
• Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signatureLi Q, Feng T, Zhu T, Zhang W, Qian Y, Zhang H, Zheng X, Li D, Yun X, Zhao J, Li Y, Yu H, Gao M, Qian B. Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature. Journal Of Translational Medicine 2023, 21: 206. PMID: 36941725, PMCID: PMC10026500, DOI: 10.1186/s12967-023-04045-2.
• Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer.Jung S, Papp J, Sobel E, Pellegrini M, Yu H. Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer. Endocrine Related Cancer 2023, 30 PMID: 36705562, PMCID: PMC10095926, DOI: 10.1530/erc-22-0184.
• Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder CancerMurakami K, Furuya H, Hokutan K, Goodison S, Pagano I, Chen R, Shen C, Chan M, Ng C, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, Wang Z, Yu H, Rosser C. Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer. International Journal Of Molecular Sciences 2023, 24: 4943. PMID: 36902377, PMCID: PMC10003630, DOI: 10.3390/ijms24054943.
• Pathogenesis to management of hepatocellular carcinomaDa B, Suchman K, Lau L, Rabiee A, He A, Shetty K, Yu H, Wong L, Amdur R, Crawford J, Fox S, Grimaldi G, Shah P, Weinstein J, Bernstein D, Satapathy S, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes & Cancer 2022, 13: 72-87. PMID: 36533190, PMCID: PMC9746873, DOI: 10.18632/genesandcancer.226.
• Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysisBrasky T, Hade E, Cohn D, Newton A, Petruzella S, O'Connell K, Bertrand K, Cook L, De Vivo I, Du M, Freudenheim J, Friedenreich C, Goodman M, Gorzelitz J, Ibiebele T, Krogh V, Liao L, Lipworth L, Lu L, McCann S, O'Mara T, Palmer J, Ponte J, Prizment A, Risch H, Sandin S, Schouten L, Setiawan V, Shu X, Trabert B, van den Brandt P, Webb P, Wentzensen N, Wilkens L, Wolk A, Yu H, Neuhouser M. Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis. Gynecologic Oncology 2022, 169: 137-146. PMID: 36934308, PMCID: PMC10025515, DOI: 10.1016/j.ygyno.2022.10.015.
• d-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitroZhu T, Li Y, Feng T, Yang Y, Zhang K, Gao J, Quan X, Qian Y, Yu H, Qian B. d-Limonene inhibits the occurrence and progression of LUAD through suppressing lipid droplet accumulation induced by PM2.5 exposure in vivo and in vitro. Respiratory Research 2022, 23: 338. PMID: 36496421, PMCID: PMC9741803, DOI: 10.1186/s12931-022-02270-9.
• Abstract 2544: TGF-β receptors 1 and 2 are functional biomarkers that stratify risk of hepatocellular cancer (HCC). Artificial intelligence based validation at three centersZaidi S, Shetty K, Yu H, Wong L, Rao S, Jogunoori W, Amdur R, Li S, latham P, Nguyen B, Mishra L. Abstract 2544: TGF-β receptors 1 and 2 are functional biomarkers that stratify risk of hepatocellular cancer (HCC). Artificial intelligence based validation at three centers. Cancer Research 2021, 81: 2544-2544. DOI: 10.1158/1538-7445.am2021-2544.
• P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) studySarink D, Le Marchand L, Cheng I, Wu A, Franke A, Wilkens L, White K, Yu H, Merritt M. P76 Prospective investigation of pre-diagnostic urinary bisphenol a and phthalates in relation to endometrial cancer risk in the multiethnic cohort (MEC) study. International Journal Of Gynecological Cancer 2019, 29: a101. DOI: 10.1136/ijgc-2019-esgo.138.
• Abstract 3156: Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerShetty K, Deng C, Jogunoori W, Amdur R, Resar L, Latham P, Mazumder R, Horvath A, Nguyen B, Li S, Wu X, Yu H, Wong L, White J, Silver S, Rashid A, Kundra V, Wang X, Mishra L. Abstract 3156: Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer. Cancer Research 2019, 79: 3156-3156. DOI: 10.1158/1538-7445.am2019-3156.
• Abstract 3156: Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerShetty K, Deng C, Jogunoori W, Amdur R, Resar L, Latham P, Mazumder R, Horvath A, Nguyen B, Li S, Wu X, Yu H, Wong L, White J, Silver S, Rashid A, Kundra V, Wang X, Mishra L. Abstract 3156: Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer. 2019, 3156-3156. DOI: 10.1158/1538-7445.sabcs18-3156.
• Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial.Huang G, Merritt M, Hutson A, Strickler H, Einstein M, Brouwer-Visser J, Ramirez N, Lankes H, El-Bahrawy M, Xue X, Yu H, Mannel R, O'Malley D, Mutch D, Disilvestro P, Geller M, Guntupalli S, Birrer M, Miller D, Gunter M. Sex hormone, insulin, and insulin-like growth factor signaling in recurrence of high stage endometrial cancer: Results from the NRG Oncology/Gynecologic Oncology Group 210 trial. Journal Of Clinical Oncology 2019, 37: 5509-5509. DOI: 10.1200/jco.2019.37.15_suppl.5509.
• Mo1435 – Pathway Specific Functional Biomarkers for the Early Detection of Liver CancerRao S, Shetty K, Deng C, Jogunoori W, Amdur R, Resar L, Latham P, Mazumder R, Horvath A, Nguyen B, Zaidi S, Li S, Yu H, Wong L, White J, Rashid A, Kundra V, Wang X, Mishra L. Mo1435 – Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer. Gastroenterology 2019, 156: s-1306. DOI: 10.1016/s0016-5085(19)40276-x.
• 1352P A serum miRNA biomarker panel for the detection of early stage non-small cell lung cancerYing L, Zou R, Du L, Shi L, Zhang N, Jin J, Wu J, Zhang F, Chen K, Huang M, Zhang Y, Lin A, Yu H, Zhou L, Mao W, Su D. 1352P A serum miRNA biomarker panel for the detection of early stage non-small cell lung cancer. Annals Of Oncology 2018, 29: viii484. DOI: 10.1093/annonc/mdy290.003.
• A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, Shi Y, Shen Y, Liu X, Lai W, Yang R, Xiao D, Cheng Y, Liu S, Zhou H, Cao Y, Yu W, Muegge K, Yu H, Tao Y. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53. Cancer Research 2018, 78: canres.3454.2017. PMID: 29588351, PMCID: PMC8073197, DOI: 10.1158/0008-5472.can-17-3454.
• Food withdrawal alters the gut microbiota and metabolome in miceZheng X, Zhou K, Zhang Y, Han X, Zhao A, Liu J, Qu C, Ge K, Huang F, Hernandez B, Yu H, Panee J, Chen T, Jia W, Jia W. Food withdrawal alters the gut microbiota and metabolome in mice. The FASEB Journal 2018, 32: 4878-4888. PMID: 29620942, PMCID: PMC9292403, DOI: 10.1096/fj.201700614r.
• D-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancerYu X, Lin H, Wang Y, Lv W, Zhang S, Qian Y, Deng X, Feng N, Yu H, Qian B. D-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer. OncoTargets And Therapy 2018, 11: 1833-1847. PMID: 29670359, PMCID: PMC5894671, DOI: 10.2147/ott.s155716.
• Abstract P5-07-03: WithdrawnYu H, Katsaros D, Biglia N, Shen Y, Loo L, Yu X, Lin H, Fu Y, Chu W, Fei P, Ni Y, Jia W, Deng X, Qian B, Wang Z. Abstract P5-07-03: Withdrawn. Cancer Research 2018, 78: p5-07-03-p5-07-03. DOI: 10.1158/1538-7445.sabcs17-p5-07-03.
• Genome-wide analysis of DNA methylation and their associations with long noncoding RNA/mRNA expression in non-small-cell lung cancerFeng N, Wang Y, Zheng M, Yu X, Lin H, Ma R, Shi O, Zheng X, Gao M, Yu H, Garmire L, Qian B. Genome-wide analysis of DNA methylation and their associations with long noncoding RNA/mRNA expression in non-small-cell lung cancer. Epigenomics 2017, 9: 137-153. PMID: 28111977, DOI: 10.2217/epi-2016-0120.
• Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung CancerFeng N, Ching T, Wang Y, Liu B, Lin H, Shi O, Zhang X, Zheng M, Zheng X, Gao M, Zheng Z, Yu H, Garmire L, Qian B. Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer. Scientific Reports 2016, 6: 37233. PMID: 27849024, PMCID: PMC5110979, DOI: 10.1038/srep37233.
• Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosisYing L, Zhang F, Pan X, Chen K, Zhang N, Jin J, Wu J, Feng J, Yu H, Jin H, Su D. Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget 2016, 5: 86536-86546. PMID: 27852032, PMCID: PMC5349933, DOI: 10.18632/oncotarget.13294.
• Effects of Physical Activity on DNA Methylation and Associations with Breast CancerYu H, Irwin M. Effects of Physical Activity on DNA Methylation and Associations with Breast Cancer. 2016, 11: 251-264. DOI: 10.1007/978-3-319-41610-6_11.
• Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.Kalachand R, Ruscito I, Dimitrova D, Benedetti Panici P, Sehouli J, Olek S, Braicu E, Lu L, Katsaros D, Yu H, Carey M, Broaddus R, Lu K, Mills G, Harrell M, Agnew K, Swisher E, Grogan W, Stordal B, Hennessy B. Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. Journal Of Clinical Oncology 2015, 33: 5526-5526. DOI: 10.1200/jco.2015.33.15_suppl.5526.
• A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast CancerHuang S, Yee C, Ching T, Yu H, Garmire L. A Novel Model to Combine Clinical and Pathway-Based Transcriptomic Information for the Prognosis Prediction of Breast Cancer. PLOS Computational Biology 2014, 10: e1003851. PMID: 25233347, PMCID: PMC4168973, DOI: 10.1371/journal.pcbi.1003851.
• Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokersXu F, Zhang H, Su Y, Kong J, Yu H, Qian B. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clinical And Translational Oncology 2014, 16: 980-985. PMID: 24805982, DOI: 10.1007/s12094-014-1183-9.
• The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.
• Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-SmokersZhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers. PLOS ONE 2013, 8: e81408. PMID: 24282590, PMCID: PMC3839880, DOI: 10.1371/journal.pone.0081408.
• Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular CarcinomaSong M, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong L. Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma. PLOS ONE 2013, 8: e55761. PMID: 23437062, PMCID: PMC3577824, DOI: 10.1371/journal.pone.0055761.
• Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancerYING L, SU D, ZHU J, MA S, KATSAROS D, YU H. Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncology Letters 2013, 5: 1315-1320. PMID: 23599786, PMCID: PMC3629093, DOI: 10.3892/ol.2013.1144.
• Abstract 14: Body mass index and type 2 diabetes genetic risk scores and endometrial cancer risk among women of European ancestry.Prescott J, Setiawan V, Wentzensen N, Schumacher F, Yu H, Delahanty R, Chanock S, Chen C, Garcia-Closas M, Haiman C, Hartge P, Horn-Ross P, Le Marchand L, Lissowska J, Lu L, Risch H, Shu X, Ursin G, Weiss N, Yang H, Kraft P, De Vivo I. Abstract 14: Body mass index and type 2 diabetes genetic risk scores and endometrial cancer risk among women of European ancestry. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 14-14. DOI: 10.1158/1055-9965.gwas-14.
• Meta-Analysis of the Association between Mir-196a-2 Polymorphism and Cancer SusceptibilityZhang H, Su Y, Yu H, Qian B. Meta-Analysis of the Association between Mir-196a-2 Polymorphism and Cancer Susceptibility. Cancer Biology & Medicine 2012, 9: 63-72. PMID: 23691458, PMCID: PMC3643645, DOI: 10.3969/j.issn.2095-3941.2012.01.012.
• PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancerSu D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.
• Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. Retraction to “A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer” [Gynecol. Oncol. 120 (2011) S3]. Gynecologic Oncology 2011, 122: 205. PMID: 21770066, DOI: 10.1016/j.ygyno.2011.03.028.
• Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese womenQian B, Zheng H, Yu H, Chen K. Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women. Breast Cancer Research And Treatment 2011, 130: 217. PMID: 21562710, DOI: 10.1007/s10549-011-1552-9.
• RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancerRatner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer. Gynecologic Oncology 2011, 120: s3. DOI: 10.1016/j.ygyno.2010.12.010.
• Relationship of folate, vitamin B12 and methylation of insulin-like growth factor-II in maternal and cord bloodBa Y, Yu H, Liu F, Geng X, Zhu C, Zhu Q, Zheng T, Ma S, Wang G, Li Z, Zhang Y. Relationship of folate, vitamin B12 and methylation of insulin-like growth factor-II in maternal and cord blood. European Journal Of Clinical Nutrition 2011, 65: 480-485. PMID: 21245875, PMCID: PMC3071883, DOI: 10.1038/ejcn.2010.294.
• Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer riskQian B, Zhang H, Zhang L, Zhou X, Yu H, Chen K. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 2010, 73: 138-146. PMID: 21195504, DOI: 10.1016/j.lungcan.2010.11.018.
• Abstract B70: Physical activity and BMI in a population-based case-control study of endometrial cancer riskArem H, Irwin M, Zhou Y, Lu L, Risch H, Yu H. Abstract B70: Physical activity and BMI in a population-based case-control study of endometrial cancer risk. Cancer Prevention Research 2010, 3: b70-b70. DOI: 10.1158/1940-6207.prev-10-b70.
• A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer RiskRatner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.
• Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP.Schwartz P, Glasgow M, Yu H, Rutherford T, Azodi M, Silasi D, Santin A. Neoadjuvant carboplatin and paclitaxel (CP) chemotherapy (NACT) in patients (pts) with advancedstage (AS) epithelial ovarian cancer (EOC) compared with upfront surgical cytoreduction (USC) followed by CP. Journal Of Clinical Oncology 2010, 28: e15511-e15511. DOI: 10.1200/jco.2010.28.15_suppl.e15511.
• ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control StudyRisch HA, Yu H, Lu L, Kidd MS. ABO Blood Group, Helicobacter pylori Seropositivity, and Risk of Pancreatic Cancer: A Case–Control Study. Journal Of The National Cancer Institute 2010, 102: 502-505. PMID: 20181960, PMCID: PMC2902822, DOI: 10.1093/jnci/djq007.
• Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, Zheng W, Blot WJ. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine Related Cancer 2010, 17: 51-60. PMID: 19786462, PMCID: PMC2814999, DOI: 10.1677/erc-09-0023.
• A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF, Hoover RN, Hartge P, Chanock SJ. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics 2010, 42: 224-228. PMID: 20101243, PMCID: PMC2853179, DOI: 10.1038/ng.522.
• Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer PatientsRichter C, Qian B, Martel M, Yu H, Azodi M, Rutherford T, Schwartz P. Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients. Obstetrical & Gynecological Survey 2009, 64: 726-727. DOI: 10.1097/01.ogx.0000361368.51892.57.
• Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancerAmundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, LaCroix A, Zheng W, Albanes D, Bamlet W, Berg CD, Berrino F, Bingham S, Buring JE, Bracci PM, Canzian F, Clavel-Chapelon F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Fox Jr J, Gallinger S, Gaziano JM, Giovannucci EL, Goggins M, González CA, Hallmans G, Hankinson SE, Hassan M, Holly EA, Hunter DJ, Hutchinson A, Jackson R, Jacobs KB, Jenab M, Kaaks R, Klein AP, Kooperberg C, Kurtz RC, Li D, Lynch SM, Mandelson M, McWilliams RR, Mendelsohn JB, Michaud DS, Olson SH, Overvad K, Patel AV, Peeters PH, Rajkovic A, Riboli E, Risch HA, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hartge P, Hoover RN. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics 2009, 41: 986-990. PMID: 19648918, PMCID: PMC2839871, DOI: 10.1038/ng.429.
• Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxelSu D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.
• Effect Of Physical Activity On Weight And Body Composition In Breast Cancer SurvivorsCadmus L, Yu H, Wiley A, Chung G, Irwin M. Effect Of Physical Activity On Weight And Body Composition In Breast Cancer Survivors. Medicine & Science In Sports & Exercise 2009, 41: 10-11. DOI: 10.1249/01.mss.0000354254.67034.14.
• Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trialsCadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and quality of life during and after treatment for breast cancer: results of two randomized controlled trials. Psycho-Oncology 2009, 18: 343-352. PMID: 19242918, PMCID: PMC4221990, DOI: 10.1002/pon.1525.
• Randomized Controlled Trial of Aerobic Exercise on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors: The Yale Exercise and Survivorship StudyIrwin ML, Varma K, Alvarez-Reeves M, Cadmus L, Wiley A, Chung GG, DiPietro L, Mayne ST, Yu H. Randomized Controlled Trial of Aerobic Exercise on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors: The Yale Exercise and Survivorship Study. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 306-313. PMID: 19124513, PMCID: PMC2841479, DOI: 10.1158/1055-9965.epi-08-0531.
• Associations of Lin-28 Homologs with Let-7a Processing and Insulin-like Growth Factor-II Expression in Epithelial Ovarian Cancer.Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, Rigault de la Longrais IA, Preti M, Menato G, Yu H. Associations of Lin-28 Homologs with Let-7a Processing and Insulin-like Growth Factor-II Expression in Epithelial Ovarian Cancer. Eur J Cancer 2009 Aug;
• Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal WomenGunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 2008, 101: 48-60. PMID: 19116382, PMCID: PMC2639294, DOI: 10.1093/jnci/djn415.
• Adipokine genes and prostate cancer riskMoore SC, Leitzmann MF, Albanes D, Weinstein SJ, Snyder K, Virtamo J, Ahn J, Mayne ST, Yu H, Peters U, Gunter MJ. Adipokine genes and prostate cancer risk. International Journal Of Cancer 2008, 124: 869-876. PMID: 19035456, PMCID: PMC2879625, DOI: 10.1002/ijc.24043.
• High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Research And Treatment 2008, 117: 131-140. PMID: 18932017, DOI: 10.1007/s10549-008-0219-7.
• Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic SyndromeHuang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931. DOI: 10.231/jim.0b013e318182080a.
• Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic SyndromeHuang J, Parish R, Mansi I, Yu H, Kennen E, Davis T, Carden D. Non-High-Density Lipoprotein Cholesterol in Patients With Metabolic Syndrome. Journal Of Investigative Medicine 2008, 56: 931. PMID: 18753978, DOI: 10.2310/jim.0b013e318182080a.
• TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survivalMu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.
• A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial CancerGunter M, Hoover D, Yu H, Wassertheil-Smoller S, Manson J, Li J, Harris T, Rohan T, Xue X, Ho G, Einstein M, Kaplan R, Burk R, Wylie-Rosett J, Pollak M, Anderson G, Howard B, Strickler H. A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 921-929. PMID: 18398032, PMCID: PMC3090086, DOI: 10.1158/1055-9965.epi-07-2686.
• The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected womenStrickler H, Howard A, Peters M, Fazzari M, Yu H, Augenbraun M, French A, Young M, Gange S, Anastos K, Kovacs A. The insulin-like growth factor axis and risk of liver disease in hepatitis C virus/HIV-co-infected women. AIDS 2008, 22: 527-531. PMID: 18301066, PMCID: PMC3507535, DOI: 10.1097/qad.0b013e3282f22cdf.
• Associations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in WomenStrickler H, Fazzari M, Kovacs A, Isasi C, Napolitano L, Minkoff H, Gange S, Young M, Sharp G, Kaplan R, Cohen M, Gunter M, Harris T, Yu H, Schoenbaum E, Landay A, Anastos K. Associations of Insulin-Like Growth Factor (IGF)—I and IGF-Binding Protein—3 with HIV Disease Progression in Women. The Journal Of Infectious Diseases 2008, 197: 319-327. PMID: 18177247, PMCID: PMC3127259, DOI: 10.1086/524848.
• Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural HistoryHarris T, Burk R, Yu H, Minkoff H, Massad L, Watts D, Zhong Y, Gange S, Kaplan R, Anastos K, Levine A, Moxley M, Xue X, Fazzari M, Palefsky J, Strickler H. Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History. Cancer Epidemiology Biomarkers & Prevention 2008, 17: 245-248. PMID: 18199731, DOI: 10.1158/1055-9965.epi-07-0686.
• Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal WomenGunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD. Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women. Cancer Research 2008, 68: 329-337. PMID: 18172327, PMCID: PMC4225702, DOI: 10.1158/0008-5472.can-07-2946.
• ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based TherapySmith S, Su D, de la Longrais I, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. Journal Of Clinical Oncology 2007, 25: 5172-5179. PMID: 18024864, DOI: 10.1200/jco.2007.11.8547.
• Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable PrognosisLu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis. Cancer Research 2007, 67: 10117-10122. PMID: 17974952, DOI: 10.1158/0008-5472.can-07-2544.
• Insulin Resistance–Related Gene Polymorphisms and Risk of Prostate CancerMoore SC, Leitzmann MF, Weinstein SJ, Snyder K, Albanes D, Virtamo J, Graubard BI, Mayne ST, Yu H, Peters U, Gunter MJ. Insulin Resistance–Related Gene Polymorphisms and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 1315-1317. PMID: 17548707, DOI: 10.1158/1055-9965.epi-07-0191.
• Clinical oncology—A new eraQian B, Su D, Yu H. Clinical oncology—A new era. Cancer Biology & Medicine 2007, 4: 6-8. DOI: 10.1007/s11805-007-0006-y.
• IGF-I in epithelial ovarian cancer and its role in disease progressionBrokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.
• Energy balance, insulin resistance biomarkers, and breast cancer riskFair A, Dai Q, Shu X, Matthews C, Yu H, Jin F, Gao Y, Zheng W. Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Epidemiology 2007, 31: 214-219. PMID: 17646056, PMCID: PMC1994998, DOI: 10.1016/j.cdp.2007.04.003.
• Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancerWolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu Q, Li B. Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery 2006, 140: 161-169. PMID: 16904965, DOI: 10.1016/j.surg.2006.05.001.
• High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast CancerByrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson L, DeBenedetti A, Abreo F, Turnage R, McDonald J, Li B. High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer. Annals Of Surgery 2006, 243: 684-692. PMID: 16633004, PMCID: PMC1570543, DOI: 10.1097/01.sla.0000216770.23642.d8.
• Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3)Harris T, Strickler H, Yu H, Pollak M, Monrad E, Travin M, Xue X, Rohan T, Kaplan R. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Hormone & IGF Research 2006, 16: 86-92. PMID: 16530441, DOI: 10.1016/j.ghir.2006.01.002.
• Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patientsWolfort R, Chu Q, Turnage R, Yu H, Nuthalapaty S, De Benedetti A, Li B. Upregulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated breast cancer patients. Journal Of Surgical Research 2006, 130: 218-219. DOI: 10.1016/j.jss.2005.11.161.
• Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancerWILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.
• Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based ChemotherapyKelly M, O’Malley D, Hui P, McAlpine J, Yu H, Rutherford T, Azodi M, Schwartz P. Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based Chemotherapy. Obstetrical & Gynecological Survey 2006, 61: 27-29. DOI: 10.1097/01.ogx.0000193850.73725.34.
• 266 NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN THE METABOLIC SYNDROME.Huang J, Parish R, Yu H, Bass P, Mansi I, Kennen E, Davis T, Carden D. 266 NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN THE METABOLIC SYNDROME. Journal Of Investigative Medicine 2006, 54: s303. DOI: 10.2310/6650.2005.x0008.265.
• A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast CancerMcClusky D, Chu Q, Yu H, DeBenedetti A, Johnson L, Meschonat C, Turnage R, McDonald J, Abreo F, Li B. A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer. Annals Of Surgery 2005, 123: 278-286. PMID: 16192819, PMCID: PMC1402342, DOI: 10.1097/01.sla.0000184224.55949.90.
• Glutathione S-transferase polymorphisms and ovarian cancer treatment and survivalBeeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.
• IGF‐I, testosterone and breast cancer riskShi R, Yu H, McLarty J, Glass J. IGF‐I, testosterone and breast cancer risk. International Journal Of Cancer 2005, 115: 498-498. DOI: 10.1002/ijc.20833.
• Tipping the Scales: The Effect of Literacy on Obese Patients’ Knowledge and Readiness to Lose WeightKennen E, Davis T, Huang J, Yu H, Carden D, Bass R, Arnold C. Tipping the Scales: The Effect of Literacy on Obese Patients’ Knowledge and Readiness to Lose Weight. Southern Medical Journal 2005, 98: 15-18. PMID: 15678634, DOI: 10.1097/01.smj.0000146617.21240.49.
• Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancerWiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2004, 16: 210. DOI: 10.1136/ijgc-00009577-200601000-00034.
• Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese womenWen W, Gao Y, Shu X, Yu H, Cai Q, Smith J, Zheng W. Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women. International Journal Of Cancer 2004, 113: 307-311. PMID: 15386404, DOI: 10.1002/ijc.20571.
• Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancerKatsaros D, Cho W, Singal R, Fracchioli S, de la Longrais I, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology 2004, 94: 685-692. PMID: 15350359, DOI: 10.1016/j.ygyno.2004.06.018.
• Reports: Insulin-Like Growth Factor-I, Soy Protein Intake, and Breast Cancer RiskSanderson M, Shu X, Yu H, Dai Q, Malin A, Gao Y, Zheng W. Reports: Insulin-Like Growth Factor-I, Soy Protein Intake, and Breast Cancer Risk. Nutrition And Cancer 2004, 50: 8-15. PMID: 15572292, DOI: 10.1207/s15327914nc5001_2.
• IGF‐I and breast cancer: A meta‐analysisShi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.
• Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women.Ren Z, Cai Q, Shu X, Cai H, Li C, Yu H, Gao Y, Zheng W. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiology Biomarkers & Prevention 2004, 13: 1290-5. PMID: 15298948, DOI: 10.1158/1055-9965.1290.13.8.
• Correlation of Blood Sex Steroid Hormones with Body Size, Body Fat Distribution, and Other Known Risk Factors for Breast Cancer in Post-Menopausal Chinese WomenBoyapati S, Shu X, Gao Y, Dai Q, Yu H, Cheng J, Jin F, Zheng W. Correlation of Blood Sex Steroid Hormones with Body Size, Body Fat Distribution, and Other Known Risk Factors for Breast Cancer in Post-Menopausal Chinese Women. Cancer Causes & Control 2004, 15: 305-311. PMID: 15090725, DOI: 10.1023/b:caco.0000024256.48104.50.
• Evaluation of the synergistic effect of insulin resistance and insulin‐like growth factors on the risk of breast carcinomaMalin A, Dai Q, Yu H, Shu X, Jin F, Gao Y, Zheng W. Evaluation of the synergistic effect of insulin resistance and insulin‐like growth factors on the risk of breast carcinoma. Cancer 2004, 100: 694-700. PMID: 14770423, PMCID: PMC1780270, DOI: 10.1002/cncr.20023.
• Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care ClinicsHuang J, Yu H, Marin E, Brock S, Carden D, Davis T. Physicians’ Weight Loss Counseling in Two Public Hospital Primary Care Clinics. Academic Medicine 2004, 79: 156-161. PMID: 14744717, DOI: 10.1097/00001888-200402000-00012.
• TLK1B is elevated with eIF4E overexpression in breast cancerNorton K, McClusky D, Sen S, Yu H, Meschonat C, Debenedetti A, Li B. TLK1B is elevated with eIF4E overexpression in breast cancer. Journal Of Surgical Research 2004, 116: 98-103. PMID: 14732354, DOI: 10.1016/j.jss.2003.08.001.
• Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women.Zheng S, Zheng W, Chang B, Shu X, Cai Q, Yu H, Dai Q, Xu J, Gao Y. Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Research 2003, 63: 7624-9. PMID: 14633679.
• Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)Li L, Yu H, Schumacher F, Casey G, Witte J. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes & Control 2003, 14: 721-726. PMID: 14674736, DOI: 10.1023/a:1026383824791.
• Prevalence of Overweight, Obesity, and Associated Diseases among Outpatients in a Public HospitalHuang J, Marin E, Yu H, Carden D, Arnold C, Davis T, Banks D. Prevalence of Overweight, Obesity, and Associated Diseases among Outpatients in a Public Hospital. Southern Medical Journal 2003, 96: 558-562. PMID: 12938782, DOI: 10.1097/01.smj.0000054725.35262.d4.
• Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics.Dai Q, Franke A, Yu H, Shu X, Jin F, Hebert J, Custer L, Gao Y, Zheng W. Urinary phytoestrogen excretion and breast cancer risk: evaluating potential effect modifiers endogenous estrogens and anthropometrics. Cancer Epidemiology Biomarkers & Prevention 2003, 12: 497-502. PMID: 12814993.
• Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) geneKato I, Eastham J, Li B, Smith M, Yu H. Genotype–phenotype analysis for the polymorphic CA repeat in the insulin-like growth factor-I (IGF-I) gene. European Journal Of Epidemiology 2003, 18: 203-209. PMID: 12800944, DOI: 10.1023/a:1023379100539.
• Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer RiskWu X, Yu H, Makan N, Spitz M. Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk. 2003, 75: 279-287. PMID: 12407747, DOI: 10.1385/1-59259-324-0:279.
• Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors.Chang S, Wu X, Yu H, Spitz M. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiology Biomarkers & Prevention 2002, 11: 758-66. PMID: 12163330.
• Insulin Resistance, IGFs and Energy Balance on the Risk of Breast CancerMalin A, Zheng W, Yu H. Insulin Resistance, IGFs and Energy Balance on the Risk of Breast Cancer. 2002 DOI: 10.21236/ada406834.
• Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer OutcomeLi B, Gruner J, Abreo F, Johnson L, Yu H, Nawas S, McDonald J, DeBenedetti A. Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome. Annals Of Surgery 2002, 235: 732-739. PMID: 11981220, PMCID: PMC1422500, DOI: 10.1097/00000658-200205000-00016.
• Polymorphic CA repeats in the IGF-I gene and breast cancerYu H, Li B, Smith M, Shi R, Berkel H, Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research And Treatment 2001, 70: 117-122. PMID: 11768601, DOI: 10.1023/a:1012947027213.
• Insulin-like growth factor-I and prostate cancer: a meta-analysisShi R, Berkel H, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. British Journal Of Cancer 2001, 85: 991-996. PMID: 11592771, PMCID: PMC2375097, DOI: 10.1054/bjoc.2001.1961.
• Sequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite ElementYousef G, Bharaj B, Yu H, Poulopoulos J, Diamandis E. Sequence Analysis of the Human Kallikrein Gene Locus Identifies a Unique Polymorphic Minisatellite Element. Biochemical And Biophysical Research Communications 2001, 285: 1321-1329. PMID: 11478802, DOI: 10.1006/bbrc.2001.5321.
• The relation of type 2 diabetes and cancer.Strickler H, Wylie-Rosett J, Rohan T, Hoover D, Smoller S, Burk R, Yu H. The relation of type 2 diabetes and cancer. Diabetes Technology & Therapeutics 2001, 3: 263-74. PMID: 11478333, DOI: 10.1089/152091501300209633.
• Free insulin‐like growth factor‐I and breast cancer riskLi B, Khosravi M, Berkel H, Diamandi A, Dayton M, Smith M, Yu H. Free insulin‐like growth factor‐I and breast cancer risk. International Journal Of Cancer 2001, 91: 736-739. PMID: 11267989, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1111>3.0.co;2-#.
• IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survivalKatsaros D, Yu H, Levesque M, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi M, Diamandi A, Gordini G, Diamandis E, Massobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. European Journal Of Cancer 2001, 37: 478-485. PMID: 11267857, DOI: 10.1016/s0959-8049(00)00423-8.
• Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrenceYu H, Nicar M, Shi R, Berkel H, Nam R, Trachtenberg J, Diamandis E. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57: 471-475. PMID: 11248622, DOI: 10.1016/s0090-4295(00)01003-7.
• Role of the Insulin-Like Growth Factor Family in Cancer Development and ProgressionYu H, Rohan T. Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression. Journal Of The National Cancer Institute 2000, 92: 1472-1489. PMID: 10995803, DOI: 10.1093/jnci/92.18.1472.
• Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals.Obiezu C, Giltay E, Magklara A, Scorilas A, Gooren L, Yu H, Howarth D, Diamandis E. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. Clinical Chemistry 2000, 46: 859-62. PMID: 10839777, DOI: 10.1093/clinchem/46.6.859.
• Patient Compliance Is Critical for Equivalent Clinical Outcomes for Breast Cancer Treated by Breast-Conservation TherapyLi B, Brown W, Ampil F, Burton G, Yu H, McDonald J. Patient Compliance Is Critical for Equivalent Clinical Outcomes for Breast Cancer Treated by Breast-Conservation Therapy. Annals Of Surgery 2000, 231: 883-889. PMID: 10816632, PMCID: PMC1421078, DOI: 10.1097/00000658-200006000-00013.
• Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer RiskWu X, Yu H, Amos C, Hong W, Spitz M. Joint Effect of Insulin-Like Growth Factors and Mutagen Sensitivity in Lung Cancer Risk. Journal Of The National Cancer Institute 2000, 92: 737-743. PMID: 10793110, DOI: 10.1093/jnci/92.9.737.
• DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALSOBIEZU C, GILTAY E, MAGKLARA A, SCORILAS A, GOOREN L, YU H, DIAMANDIS E. DRAMATIC SUPPRESSION OF PLASMA AND URINARY PROSTATE SPECIFIC ANTIGEN AND HUMAN GLANDULAR KALLIKREIN BY ANTIANDROGENS IN MALE-TO-FEMALE TRANSSEXUALS. Journal Of Urology 2000, 163: 802. DOI: 10.1097/00005392-200003000-00023.
• Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-upVassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.
• p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancerAngelopoulou K, Yu H, Bharaj B, Giai M, Diamandis E. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 2000, 33: 53-62. PMID: 10693987, DOI: 10.1016/s0009-9120(99)00084-3.
• Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomyScorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.
• Clinical implications of prostate-specific antigen in men and women.Yu H. Clinical implications of prostate-specific antigen in men and women. Journal Of Gender-Specific Medicine 2000, 3: 45-8, 53. PMID: 11253246.
• Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer riskWu X, Yu H, Amos C, Hong W, Spitz M. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk. Growth Hormone & IGF Research 2000, 10: s26-s27. PMID: 10984281, DOI: 10.1016/s1096-6374(00)90012-1.
• Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancerYu H, Bharaj B, Vassilikos E, Giai M, Diamandis E. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Research And Treatment 2000, 59: 153-161. PMID: 10817350, DOI: 10.1023/a:1006356502820.
• Elevated estradiol and testosterone levels and risk for breast cancer.Yu H, Diamandis E, Hoffman B. Elevated estradiol and testosterone levels and risk for breast cancer. Annals Of Internal Medicine 1999, 131: 715. PMID: 10577342, DOI: 10.7326/0003-4819-131-9-199911020-00023.
• Re: Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial CellsYu H. Re: Cyclin D1 Proteolysis: a Retinoid Chemoprevention Signal in Normal, Immortalized, and Transformed Human Bronchial Epithelial Cells. Journal Of The National Cancer Institute 1999, 91: 1685-1685. PMID: 10511597, DOI: 10.1093/jnci/91.19.1685.
• Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combinationYu H, Levesque M, Clark G, Diamandis E. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. British Journal Of Cancer 1999, 81: 490-495. PMID: 10507775, PMCID: PMC2362935, DOI: 10.1038/sj.bjc.6690720.
• Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulationYu H, Mistry J, Nicar M, Khosravi M, Diamandis A, van Doorn J, Juul A. Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation. Journal Of Clinical Laboratory Analysis 1999, 13: 166-172. PMID: 10414596, PMCID: PMC6808158, DOI: 10.1002/(sici)1098-2825(1999)13:4<166::aid-jcla5>3.0.co;2-x.
• Do insulin-like growth factors mediate the effect of alcohol on breast cancer risk?Yu H, Berkel J. Do insulin-like growth factors mediate the effect of alcohol on breast cancer risk? Medical Hypotheses 1999, 52: 491-496. PMID: 10459827, DOI: 10.1054/mehy.1998.0828.
• Insulin-like growth factors and cancer.Yu H, Berkel H. Insulin-like growth factors and cancer. Journal Of The Louisiana State Medical Society 1999, 151: 218-23. PMID: 10234899.
• Prostate-specific antigen (PSA) in women.Yu H, Berkel H. Prostate-specific antigen (PSA) in women. Journal Of The Louisiana State Medical Society 1999, 151: 209-13. PMID: 10234897.
• Seminal plasma biochemical markers and their association with semen analysis findingsDiamandis E, Arnett W, Foussias G, Pappas H, Ghandi S, Melegos D, Mullen B, Yu H, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. Urology 1999, 53: 596-603. PMID: 10096390, DOI: 10.1016/s0090-4295(98)00550-0.
• Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinomaDiamandis E, Helle S, Yu H, Melegos D, Lundgren S, Lonning P. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 1999, 85: 891-898. PMID: 10091767, DOI: 10.1002/(sici)1097-0142(19990215)85:4<891::aid-cncr17>3.0.co;2-k.
• Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast diseaseBorchert G, Yu H, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis E. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. Journal Of Clinical Laboratory Analysis 1999, 13: 75-81. PMID: 10102136, PMCID: PMC6807928, DOI: 10.1002/(sici)1098-2825(1999)13:2<75::aid-jcla6>3.0.co;2-f.
• Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classificationBorchert G, Melegos D, Yu H, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis E. Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. Clinical Biochemistry 1999, 32: 39-44. PMID: 10074890, DOI: 10.1016/s0009-9120(98)00079-4.
• Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancerFoekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.
• Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control AnalysisYu H, Spitz M, Mistry J, Gu J, Hong W, Wu X. Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: a Case-Control Analysis. Journal Of The National Cancer Institute 1999, 91: 151-156. PMID: 9923856, DOI: 10.1093/jnci/91.2.151.
• Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.Lianidou E, Levesque M, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis E. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Research 1999, 19: 749-56. PMID: 10216487.
• Insulin‐like growth factor–binding protein‐3 and breast cancer survivalYu H, Levesque M, Khosravi M, Papanastasiou‐Diamandi A, Clark G, Diamandis E. Insulin‐like growth factor–binding protein‐3 and breast cancer survival. International Journal Of Cancer 1998, 79: 624-628. PMID: 9842972, DOI: 10.1002/(sici)1097-0215(19981218)79:6<624::aid-ijc12>3.0.co;2-9.
• The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone DeficiencyJuul A, Møller S, Mosfeldt-Laursen E, Rasmussen M, Scheike T, Pedersen S, Kastrup K, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebæk N. The Acid-Labile Subunit of Human Ternary Insulin-Like Growth Factor Binding Protein Complex in Serum: Hepatosplanchnic Release, Diurnal Variation, Circulating Concentrations in Healthy Subjects, and Diagnostic Use in Patients with Growth Hormone Deficiency. The Journal Of Clinical Endocrinology & Metabolism 1998, 83: 4408-4415. PMID: 9851786, DOI: 10.1210/jcem.83.12.5311.
• The significance of prostate specific antigen (PSA) in breast cancerKlijn J, Diamandis E, Yu H, Look M, Gelder M, van Putten W, Foekens J. The significance of prostate specific antigen (PSA) in breast cancer. European Journal Of Cancer 1998, 34: s106-s107. DOI: 10.1016/s0959-8049(98)80440-1.
• Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.Yu H, Levesque M, Clark G, Diamandis E. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research 1998, 4: 1489-97. PMID: 9626467.
• Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patientsLevesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.
• NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGENDiamandis E, Yu H. NONPROSTATIC SOURCES OF PROSTATE-SPECIFIC ANTIGEN. Urologic Clinics Of North America 1997, 24: 275-282. PMID: 9126224, DOI: 10.1016/s0094-0143(05)70373-6.
• Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./lYu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918.. DOI: 10.1097/00005392-199703000-00047.
• Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./lYu H, Diamandis E, Wong P, Nam R, Trachtenberg J. Detection of Prostate Cancer Relapse With Prostate Specific Antigen Monitoring at Levels of 0.001 to 0.1 micro g./l. Journal Of Urology 1997, 157: 913-918. PMID: 9072598, DOI: 10.1016/s0022-5347(01)65082-1.
• Prostate-specific antigen in amniotic fluid of normal and abnormal pregnanciesMelegos D, Yu H, Allen L, Diamandis E. Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clinical Biochemistry 1996, 29: 555-562. PMID: 8939403, DOI: 10.1016/s0009-9120(96)00093-8.
• Circulating antibodies against p53 protein in patients with ovarian carcinomaAngelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis E. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Cancer 1996, 78: 2146-2152. PMID: 8918407, DOI: 10.1002/(sici)1097-0142(19961115)78:10<2146::aid-cncr15>3.0.co;2-z.
• Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancerYu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.
• Prostate specific antigen — a new constituent of breast cyst fluidDiamandis E, Yu H, López-Otín C. Prostate specific antigen — a new constituent of breast cyst fluid. Breast Cancer Research And Treatment 1996, 38: 259-264. PMID: 8739078, DOI: 10.1007/bf01806144.
• Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalitiesMelegos D, Yu H, Diamandis E. Prostaglandin D2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. Clinical Chemistry 1996, 42: 1042-1050. PMID: 8674187, DOI: 10.1093/clinchem/42.7.1042.
• Ultrasensitive prostate-specific antigen assays and their clinical applicationDiamandis E, Yu H, Melegos D. Ultrasensitive prostate-specific antigen assays and their clinical application. Clinical Chemistry 1996, 42: 853-857. PMID: 8665675, DOI: 10.1093/clinchem/42.6.853.
• Prostate specific antigen in breast cancer, benign breast disease and normal breast tissueYu H, Diamandis E, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Research And Treatment 1996, 40: 171-178. PMID: 8879683, DOI: 10.1007/bf01806212.
• Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancersFerguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.
• Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screeningHoffman B, Yu H, Diamandis E. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clinical Chemistry 1996, 42: 536-544. PMID: 8605670, DOI: 10.1093/clinchem/42.4.536.
• Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patientsZarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.
• ReDiamandis E, Yu H. Re. Journal Of Urology 1996, 155: 294.. DOI: 10.1097/00005392-199601000-00115.
• Does prostate cancer start at puberty?Diamandis E, Yu H. Does prostate cancer start at puberty? Journal Of Clinical Laboratory Analysis 1996, 10: 468-469. PMID: 8951622, DOI: 10.1002/(sici)1098-2825(1996)10:6<468::aid-jcla27>3.0.co;2-u.
• Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994Diamandis E, Yu H. Re: The Clinical Usefulness of Prostate Specific Antigen: Update 1994. Journal Of Urology 1996, 155: 294. PMID: 7490867, DOI: 10.1016/s0022-5347(01)66636-9.
• Prostate-specific antigen in serum of women with breast cancerGiai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque M, Diamandis E. Prostate-specific antigen in serum of women with breast cancer. British Journal Of Cancer 1995, 72: 728-731. PMID: 7545417, PMCID: PMC2033864, DOI: 10.1038/bjc.1995.401.
• Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicatorsLevesque M, Clark G, Yu H, Diamandis E. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal Of Cancer 1995, 72: 720-727. PMID: 7545416, PMCID: PMC2033897, DOI: 10.1038/bjc.1995.400.
• Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric techniqueZarghami N, Yu H, Diamandis E, Sutherland D. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clinical Biochemistry 1995, 28: 243-253. PMID: 7554242, DOI: 10.1016/0009-9120(95)00010-7.
• Prostate specific antigen gene expression in ovarian cancer post-liver transplantationYu H, Diamandis E, Levesquel M, Asal S, Monne M, Croce C. Prostate specific antigen gene expression in ovarian cancer post-liver transplantation. Clinical Biochemistry 1995, 28: 341. DOI: 10.1016/0009-9120(95)91407-t.
• Association between breast cancer patient survival and levels of creatine kinase BB in tumor cytosolsZarghami N, Giai M, Yu H, Katsaros D, Diamandis E. Association between breast cancer patient survival and levels of creatine kinase BB in tumor cytosols. Clinical Biochemistry 1995, 28: 341. DOI: 10.1016/0009-9120(95)91406-s.
• Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.
• Prostate-specific antigen and lack of specificity for prostate cellsDiamandis E, Yu H. Prostate-specific antigen and lack of specificity for prostate cells. The Lancet 1995, 345: 1186. PMID: 7536878, DOI: 10.1016/s0140-6736(95)91021-2.
• Expression of the prostate-specific antigen gene by a primary ovarian carcinoma.Yu H, Diamandis E, Levesque M, Asa S, Monne M, Croce C. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Research 1995, 55: 1603-6. PMID: 7536128.
• Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinomaLevesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.
• Original ArticlesYu H, Diamandis E. Original Articles. Journal Of Urology 1995, 1004-1008. DOI: 10.1097/00005392-199503001-00026.
• Original ArticlesYu H, Diamandis E. Original Articles. Journal Of Urology 1995, 153: 1004-1008.. DOI: 10.1097/00005392-199503000-00026.
• Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomyYu H, Diamandis E, Prestigiacomo A, Stamey T. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clinical Chemistry 1995, 41: 430-434. PMID: 7533672, DOI: 10.1093/clinchem/41.3.430.
• Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay TechniqueYu H, Diamandis E. Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique. Journal Of Urology 1995, 153: 1004-1008. PMID: 7531781, DOI: 10.1016/s0022-5347(01)67622-5.
• Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast (∗)Yu H, Diamandis E, Monne M, Croce C. Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast (∗). Journal Of Biological Chemistry 1995, 270: 6615-6618. PMID: 7534765, DOI: 10.1074/jbc.270.12.6615.
• Prostate-specific antigen immunoreactivity in amniotic fluidYu H, Diamandis E. Prostate-specific antigen immunoreactivity in amniotic fluid. Clinical Chemistry 1995, 41: 204-210. PMID: 7533063, DOI: 10.1093/clinchem/41.2.204.
• Prostate-specific antigen in milk of lactating womenYu H, Diamandis E. Prostate-specific antigen in milk of lactating women. Clinical Chemistry 1995, 41: 54-58. PMID: 7529146, DOI: 10.1093/clinchem/41.1.54.
• Immunoreactive prostate‐specific antigen in lung tumorsLevesque M, Yu H, D'Costa M, Tadross L, Diamandis E. Immunoreactive prostate‐specific antigen in lung tumors. Journal Of Clinical Laboratory Analysis 1995, 9: 375-379. PMID: 8587005, DOI: 10.1002/jcla.1860090607.
• Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient ageYu H, Diamandis E, Sutherland D. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clinical Biochemistry 1994, 27: 75-79. PMID: 7520846, DOI: 10.1016/0009-9120(94)90015-9.
• Detection of prostate-specific antigen immunoreactivity in breast tumorsDiamandis E, Yu H, Sutherland D. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Research And Treatment 1994, 32: 301-310. PMID: 7532468, DOI: 10.1007/bf00666007.
• Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovaryYu H, Diamandis E, Levesque M, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. Journal Of Clinical Laboratory Analysis 1994, 8: 251-253. PMID: 7523638, DOI: 10.1002/jcla.1860080412.
• Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancerLevesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.
• Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell linesYu H, Diamandis E, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Research And Treatment 1994, 32: 291-300. PMID: 7532467, DOI: 10.1007/bf00666006.
• Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studiesYu H, Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clinical Chemistry 1993, 39: 2108-2114. PMID: 7691442, DOI: 10.1093/clinchem/39.10.2108.
• PCR‐detected genital papillomavirus infection: Prevalence and association with risk factors for cervical cancerRohan T, Mann V, McLaughlin J, Harnish D, Yu H, Smith D, Davis R, Shier R, Rawls W. PCR‐detected genital papillomavirus infection: Prevalence and association with risk factors for cervical cancer. International Journal Of Cancer 1991, 49: 856-860. PMID: 1660038, DOI: 10.1002/ijc.2910490609.